

Monthly letter August 31st, 2020

#### **Performances**

For legal reasons, we cannot post the performance of this share which has less than one year performance.

Potentially	lower return		Potentially hi	gher return
		4	6	7

The risk and reward profile shown is not guaranteed and may change over time.

As this Fund has less than five years performance data available, it is based on simulated volatility and is not a guide to the future risk and reward category of the Fund.

The Fund is rated 4 because its simulated historical value has shown moderate volatility.

	ment. Bloombera

Net Performance (in %)	Revel Absolute Return	Eurostoxx 600	Eonia capitalized
August 2020	+0.70%	+2.86%	-0.04%
YTD	-2.82%	-11.86%	-0.31%
Return since inception (30/09/2019)	-3.82%	-6.78%	-0.43%

Since inception		
% positive months	3	6%
% negative months 64%		4%
Best monthly performance	1.17%	Jan.20
Worst monthly performance	-2.34%	Jul.20

Risk indicators		
Annualised volatility	4.36%	
Beta (12m)	14.00%	
Sharpe ratio	-0.85	

Exposure (in %)

Beta adjusted (12M)

78.5%

-64.5%

14.0%

Cash

76.2%

-64.6%

11.6%

Long

Short

Net

Number of positions		
Longs	31	
Shorts	21	
Total	52	

Top 5 Long Positions	Sector	% NAV
DSM NV	MATERIALS	4.7%
AP MOLLER-MAERSK	INDUSTRIALS	4.5%
ROCHE	HEALTHCARE	4.4%
NOVARTIS	HEALTHCARE	4.2%
HEIDELBERGCEMENT	MATERIALS	4.1%

Top 5 Short Positions	Sector	% NAV
1	INDEX FUT Eurostoxx	-18.40%
2	INDEX FUT CAC	-7.8%
3	INDUSTRIALS/NORDICS	-3.3%
4	CHEMICALS/NORDICS	-3.0%
5	CONSUMER DISCRETIONARY/UK	-2.9%

Top 5 Contributors	in bps	Long/Short
AP MOLLER-MAERSK	+62bps	Long
HEIDELBERGCEMENT	+35bps	Long
BOUYGUES	+35bps	Long
SAMPO	+26bps	Long
INDUSTRIALS/UK	+24bps	Short

#### Portfolio Managers

Herve Ragagnon Direct: +33 (1) 88 32 73 11 Email: hragagnon@revel-am.com

Revel Asset Management 72 Rue Pierre Charron 75008 Paris France



Youssef Benhaddouch Direct: +33 (1) 88 32 73 10 Email: yb@revel-am.com

Revel Asset Management 72 Rue Pierre Charron 75008 Paris France



# Fund facts

Aiming to achieve an absolute return over the medium term through capital growth

Strategy Investing primarily in European equities and equity related securities on both a long and short basis


Domicile	Luxembourg SICAV (UCITS)
Fund Inception Date	30 September 2019
Fund currency	EUR
Currency of share classes available	EUR, GBP, USD
Fund size/Firm assets	€ 12M/ € 39M
Dealing frequency	Weekly each Friday (cut off: 12AM Luxembourg Time)/ Each last business day of each month(cut off: 12AM Luxembourg Time)
Liquidity	Weekly and last business day of the month
Minimum initial investment	Class EI: EUR 1,000,000
Minumum subsequent	Class EI: EUR 1,000


investment	Class EI: EUR 1,000
Management Fee	Class EI: 0.80%
Performance Fee	15%
Geographic limit	At least 80% of assets in Pan- Europe
Codes	

ISINs	Class EI : LU1954070022
Bloomberg Ticker	Class EI : LU1954070022












# Liquidity Information (in NAV %)



## Exposure (in NAV %)



## Historical Daily Exposure (in NAV %)





## Performance Summary

The fund returned +0.7% in August as indexes continued to push higher and shorting proved elusive. So far so good, as the central narrative of improving economic data has continued to materialize, while still playing tug-of-war with the risks associated with rising covid cases. With the exception of Financials, nearly every other European cyclical sector has undergone a "V shaped" recovery.

Interestingly, this summer's value/cyclicals rotation is quite different from the last one seen post the Great Financial crisis (March 2009). Despite massive monetary and fiscal support, the virus introduces a significant uncertainty as to the shape and duration of this recovery. Hence, the outperformance of Autos and Construction (seen as quicker recoveries) in cyclicals and the importance of "quality factor" in value names.

Longs contributed +328bps while shorts detracted -245bps, with a quite symmetric alpha contribution from both. Our hit ratio recovered to 55% from last month's low, with a strong contribution from our cyclical bets: Heidelbergcement (+35bps) and Maersk (+62bps), a recent addition from last month. For the latter, a shortage of airfreight capacity along with increasing shipping rates (+15% for the Asia spot rate in August) in a consolidated industry is boding well for 2021 contract negotiations, while high operational leverage triggers sizeable earnings revisions.

Main detractors can be found in shorts: a UK internet retailer (-75bps) and a UK hotel operator (-37bps) both used as hedges vs cheaper long investments.

The average net exposure was 16.5% and volatility remained below 5%.

### Manager Commentary

While US activity data point to an acceleration of growth, the eurozone recovery has stuttered. Cyclicals earnings revisions profile have improved, while bond yields have risen in anticipation of higher inflation, favoring the ongoing capital rotation.

Last month, we mentioned the difficulty of managing "recovery" investments in a moving "coronavirus path". We have spent a lot of time reviewing the portfolio. The challenge is indeed to hold both companies that are doing well now (Maersk) and later stage recovery names (like Sodexo or Inditex).

We have increased Maersk to 4.5% and Heidelbergcement to 4%, and added another cyclical name, auto supplier Faurecia (1.5%) which combines resilience (management track record and credibility on costs and financial targets), compelling low and relative valuation, and potential for positive earnings surprise (on the back of a stronger order book in seating).

On the short side, we continue to manage the existing positions under our strict stop loss policy, with a sizing range of 1-3%. We look forward to more market dispersion to generate some alpha in that space.

As we enter into the last quarter of the year where volatility and dispersion usually pick up, investors need to contend with several hot topics: higher inflation and risks associated to it, the US elections result (in less than 60 days), the fear of missing out from the recovery.. and the vaccine "silver bullet".

Perhaps the covid crisis epitaph will be: "Don't fight the science!"....

Thank you for your continued trust,

Best regards, Hervé Ragagnon, Youssef Benhaddouch September 4th, 2020

(\*) All contribution impacts are absolute







This document is not intended to constitute, and should not be construed as, investment advice Disclaimer: This document and the information contained in it relates to, and is being communicated by, Revel Asset Management (together with its affiliates referred to as "Revel" in this document). This document does not constitute or form part of any offer to issue or sell, or any solicitation of any offer to subscribe or purchase, any investment, nor shall it or the fact of its distribution or communication form the basis of, or be relied on in connection with any contract. Any such offer or solicitation will only be made on the basis of the relevant current offering document, which are available on Revel's website. It does not constitute investment research as defined under EU Directive 2003/125/EC.

The information and opinions contained in this document are for background purposes only, do not purport to be full or complete and no reliance should be placed on them. Revel believes that the source of this information is reliable however it gives no guarantee, representation, warranty or undertaking, either expressly or implicitly, and accepts no liability for, the accuracy, validity, timeliness, merchantability or completeness of any information or data (whether prepared by Revel or by any third party) for any particular purpose or use or that the information or data will be free from error. Any projections or analyses provided to assist the recipient of this document in evaluating the matters described herein may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results. Accordingly, any projections or analyses should not be viewed as factual and should not be relied upon as an accurate prediction of future results. No representation is being made by the inclusion of any investment strategies presented herein that any investment in such strategies will achieve performance similar to the investment strategies herein or avoid losses. There can be no assurance that the investment strategies described herein will meet their objectives generally, or avoid losses.

Past performance is no guarantee of future results

Investment in the fund involves a significant degree of risk. Potential investors must familiarize themselves with the Key Investor Information Document (KIID) and the prospectus of the fund, which are available on Revel's website. The portfolio characteristics and other figures set forth are not static and may change over time. Revel does not represent that any statistics, investment guidelines and limits disclosed herein will remain constant over time. Potential investors should inform themselves and take appropriate advice as to any applicable legal requirements and any applicable taxation and exchange control regulations in the countries of their citizenship, residence or domicile which might be relevant.